Last edition
News about " Invasive Pneumococcal Disease"
MSD's Capvaxive Receives Singapore HSA Approval for Adults Aged 18 and Above
MSD's Capvaxive receives Singapore HSA approval for active immunisation against invasive pneumococcal disease and pneumonia caused by 21 specified serotypes in adults aged 18 and above.
Invasive Pneumococcal Disease | 30/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members